EMEA-001760-PIP01-15-M02

Key facts

Invented name
Lartruvo
Active substance
Olaratumab
Therapeutic area
Oncology
Decision number
P/0139/2017
PIP number
EMEA-001760-PIP01-15-M02
Pharmaceutical form(s)
Concentrate for solution for infusion
Condition(s) / indication(s)
  • Treatment of osteosarcoma
  • Treatment of soft tissue sarcoma
Route(s) of administration
Concentrate for solution for infusion
Contact for public enquiries
Eli Lilly and Company Limited
United Kingdom
Tel. +44 (0)1276 483000
E-mail: eu_paediatric@lilly.com
Decision type
PM: decision on the application for modification of an agreed PIP

Decision

How useful was this page?

Add your rating